Adenosine A2a Receptor Protein (ADORA2A)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Adenosine A2a Receptor Protein</th>
</tr>
<tr>
<td class="label">Ligand Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Antagonists</td>
<td>Istradefylline, Caffeine, SCH58261</td>
</tr>
<tr>
<td class="label">Agonists</td>
<td>CGS21680, Regadenoson</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>VCP746</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Striatum (Caudate/Putamen)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Nucleus Accumbens</td>
<td>High</td>
</tr>
<tr>
<td class="label">Olfactory Bulb</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Cortex](/brain-regions/cortex)</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Pathway Signaling Pathways</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">PI3K/AKT</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">[NF-κB](/entities/nf-kb)</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">β-arrestin</td>
<td>Recruitment</td>
...Adenosine A2a Receptor Protein (ADORA2A)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Adenosine A2a Receptor Protein</th>
</tr>
<tr>
<td class="label">Ligand Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Antagonists</td>
<td>Istradefylline, Caffeine, SCH58261</td>
</tr>
<tr>
<td class="label">Agonists</td>
<td>CGS21680, Regadenoson</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>VCP746</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Striatum (Caudate/Putamen)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Nucleus Accumbens</td>
<td>High</td>
</tr>
<tr>
<td class="label">Olfactory Bulb</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Cortex](/brain-regions/cortex)</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Pathway Signaling Pathways</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">PI3K/AKT</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">[NF-κB](/entities/nf-kb)</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">β-arrestin</td>
<td>Recruitment</td>
</tr>
<tr>
<td class="label">Condition</td>
<td>Role</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>Anhedonia, motivation</td>
</tr>
<tr>
<td class="label">Anxiety</td>
<td>Stress response</td>
</tr>
<tr>
<td class="label">Cancer</td>
<td>Immunosuppression</td>
</tr>
<tr>
<td class="label">Stroke</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Motor symptoms</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Approval</td>
</tr>
<tr>
<td class="label">Istradefylline (Nourianz)</td>
<td>2019</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Tozadenant</td>
<td>Biotie</td>
</tr>
<tr>
<td class="label">Preladenant</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">ST1535</td>
<td>Sigma-[Tau](/proteins/tau)</td>
</tr>
<tr>
<td class="label">Vipadenant</td>
<td>Vicore</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">neurodegeneration</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-41bc2d38" style="color:#ce93d8" title="Score: 0.52">Adenosine-Astrocyte Metabolic Reset...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">65 edges</a></td>
</tr>
</table>
Introduction
Adenosine A2A Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Adenosine A2a receptor (A2AR, ADORA2A) is a Gs protein-coupled receptor that stimulates adenylate cyclase activity, increasing intracellular cAMP levels. A2AR is highly enriched in the striatum (caudate nucleus and putamen) where it plays a critical role in modulating motor control, reward processing, and habit formation. This receptor has emerged as a major therapeutic target for [Parkinson's disease](/diseases/parkinsons-disease), with the A2AR antagonist istradefylline (Nourianz) FDA-approved as an adjunct therapy. Beyond PD, A2AR modulators are being investigated for [Alzheimer's disease](/diseases/alzheimers-disease), schizophrenia, depression, and cancer immunotherapy.
Structure and Pharmacology
Receptor Architecture
A2AR is a typical GPCR with seven transmembrane domains:
- N-terminal extracellular domain: Contains glycosylation sites
- Seven transmembrane helices (TM1-TM7): Form the ligand-binding pocket
- Intracellular loops (ICL1-3): Couple to G-proteins
- C-terminal intracellular tail: Contains phosphorylation sites and palmitoylation
Ligand Binding
Structural Features
Key structural elements:
- Conserved DRY motif: Critical for G-protein coupling
- Ball-and-chain intracellular helix 8: Regulates desensitization
- Disulfide bond: Stabilizes extracellular loops
- Glycosylation: N-terminal ASN residues
Expression Pattern
Brain Distribution
A2AR shows highly region-specific expression:
Cellular Localization
- Medium spiny [neurons](/entities/neurons) (MSNs): Highest density on D2-expressing MSNs
- Glial cells: [Astrocytes](/entities/astrocytes) and [microglia](/entities/microglia) express A2AR
- Endothelial cells: Vascular A2AR regulate blood flow
- Immune cells: T cells, B cells, macrophages
Signaling Mechanisms
Primary Signaling Pathway
A2AR activates Gs/olf proteins leading to:
Adenylate cyclase activation → ↑ cAMP
Protein kinase A (PKA) activation → Phosphorylation of substrates
CREB activation → Gene transcription
PKA phosphorylation of DARPP-32 → Modulation of striatal signalingSecondary
Cross-talk with Dopamine
A2AR-D2R interaction is crucial in striatum:
- Antagonistic relationship: A2AR activation reduces D2R signaling
- Heteromer formation: A2AR-D2R receptor complexes
- Therapeutic implications: A2AR blockade enhances D2R function
Disease Associations
Parkinson's Disease
A2AR is the primary therapeutic target in PD:
- Mechanism: A2AR overactivity in PD reduces motor function
- Therapeutic strategy: A2AR antagonists restore dopaminergic tone
- Clinical use: Istradefylline as add-on to levodopa
- Benefits: Reduced "off" time, improved "on" time
Alzheimer's Disease
Emerging evidence for A2AR involvement:
- Neuroinflammation: A2AR on [microglia](/cell-types/microglia-neuroinflammation) modulates inflammation
- Amyloid pathology: A2AR affects [Aβ](/proteins/amyloid-beta) clearance
- Memory function: Hippocampal A2AR regulates memory
- Therapeutic potential: A2AR modulators in development
Schizophrenia
A2AR dysfunction implicated in schizophrenia:
- Dopamine hypothesis interaction: Striatal A2AR-D2R balance
- Cognitive deficits: Prefrontal A2AR modulation
- Negative symptoms: Possible therapeutic benefit
- Genetic associations: ADORA2A polymorphisms linked to schizophrenia
Other Conditions
Therapeutic Targeting
FDA-Approved Therapies
Clinical Pipeline
Challenges in Drug Development
Peripheral vs central effects: Limiting side effects
Species differences: Rodent vs human receptor pharmacology
[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Required for CNS indications
Cardiovascular safety: A2AR in heart and vasculatureAnimal Models
Knockout Studies
- Adora2a-/- mice: Resistant to A2AR agonist effects
- Conditional KO: Brain-specific deletion
- Humanized mice: Express human A2AR
Phenotypic Findings
- Enhanced D2R signaling
- Reduced parkinsonian symptoms
- Altered reward processing
- Modified inflammatory responses
Disease Models
- 6-OHDA lesions: A2AR antagonists protect
- MPTP toxicity: Modulation of neurodegeneration
- Transgenic models: [α-synuclein](/proteins/alpha-synuclein) overexpression
Research Directions
Receptor structure: Cryo-EM of A2AR-G protein complexes
Heteromer biology: A2AR-D2R and A2AR-A1R complexes
Biomarkers: PET ligands for A2AR imaging
Immunotherapy: A2AR antagonists in cancer
Gene therapy: Viral vector delivery approachesBackground
The study of Adenosine A2A Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[1]: https://pubmed.ncbi.nlm.nih.gov/10629201/ PMID: 10629201(https://pubmed.ncbi.nlm.nih.gov/10629201/) - A2a adenosine receptor
[2]: https://pubmed.ncbi.nlm.nih.gov/10816402/ PMID: 10816402(https://pubmed.ncbi.nlm.nih.gov/10816402/) - Striatal A2a receptors
[3]: https://pubmed.ncbi.nlm.nih.gov/15604288/ PMID: 15604288(https://pubmed.ncbi.nlm.nih.gov/15604288/) - Parkinson's disease therapy
[4]: https://pubmed.ncbi.nlm.nih.gov/17585956/ PMID: 17585956(https://pubmed.ncbi.nlm.nih.gov/17585956/) - A2a receptor structure
[5]: https://pubmed.ncbi.nlm.nih.gov/19029120/ PMID: 19029120(https://pubmed.ncbi.nlm.nih.gov/19029120/) - Therapeutic potential
[6]: https://pubmed.ncbi.nlm.nih.gov/20139464/ PMID: 20139464(https://pubmed.ncbi.nlm.nih.gov/20139464/) - Clinical trials in PD
[7]: https://pubmed.ncbi.nlm.nih.gov/23452928/ PMID: 23452928(https://pubmed.ncbi.nlm.nih.gov/23452928/) - A2a-D2a receptor interaction
[8]: https://pubmed.ncbi.nlm.nih.gov/25872154/ PMID: 25872154(https://pubmed.ncbi.nlm.nih.gov/25872154/) - Neuroinflammation
See Also
- ADORA2A Gene
- [Parkinson's Disease](/diseases/parkinsons-disease)
- Dopamine Receptors
- G-Protein Coupled Receptors
- [Striatum](/brain-regions/striatum)
- Adenosine Receptors
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Schizophrenia](/diseases/schizophrenia)
- Dyskinesias
External Links
- [UniProt: ADORA2A](https://www.uniprot.org/uniprot/P29274)
- [PDB: A2a Receptor](https://www.rcsb.org/structure/5G53)
- [GeneCards: ADORA2A](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADORA2A)
- [OMIM: ADORA2A](https://www.omim.org/entry/102776)
- [IUPHAR: A2a Receptor](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=12)